The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy
Official Title: A Randomized, Open-label, Two-arm Phase II Trial Comparing the Efficacy of Sequential Ipilimumab Versus Best Supportive Care Following First-line Chemotherapy in Subjects With Unresectable Locally Advanced/Metastatic Gastric or Gastro-esophageal Junction Cancer
Study ID: NCT01585987
Brief Summary: The purpose of the study is to compare the efficacy of Ipilimumab and standard of care as sequential or maintenance treatment immediately after first-line chemotherapy in the treatment of unresectable or metastatic gastric and gastro-esophageal cancer.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Mount Sinai Medical Center, Miami Beach, Florida, United States
Nyu Clinical Cancer Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States
Local Institution, Montpellier Cedex, , France
Local Institution, Nice Cedex 03, , France
Local Institution, Rennes, , France
Local Institution, Toulouse Cedex 09, , France
Local Institution, Mainz, , Germany
Local Institution, Hong Kong, , Hong Kong
Local Institution, Firenze, , Italy
Local Institution, Milano, , Italy
Local Institution, Padova, , Italy
Local Institution, Pisa, , Italy
Local Institution, Roma, , Italy
Local Institution, Nagoya, Aichi, Japan
Local Institution, Saku-shi, Nagano, Japan
Local Institution, Osaka-sayama-shi, Osaka, Japan
Local Institution, Kitaadachi-gun, Saitama, Japan
Local Institution, Gyeonggi-do, , Korea, Republic of
Local Institution, Gyeonggi-do, , Korea, Republic of
Local Institution, Seoul, , Korea, Republic of
Local Institution, Seoul, , Korea, Republic of
Local Institution, Seoul, , Korea, Republic of
Local Institution, Katowice, Ochojec, Poland
Local Institution, Krakow, , Poland
Local Institution, Lodz, , Poland
Local Institution, Olsztyn, , Poland
Local Institution, Moscow, , Russian Federation
Local Institution, Singapore, , Singapore
Local Institution, Singapore, , Singapore
Local Institution, Barcelona, , Spain
Local Institution, Madrid, , Spain
Local Institution, Madrid, , Spain
Local Institution, Taipei, , Taiwan
Local Institution, Taipei, , Taiwan
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR